These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 24711253)

  • 21. Surveillance imaging of Hodgkin lymphoma patients in first remission: a clinical and economic analysis.
    Lee AI; Zuckerman DS; Van den Abbeele AD; Aquino SL; Crowley D; Toomey C; Lacasce AS; Feng Y; Neuberg DS; Hochberg EP
    Cancer; 2010 Aug; 116(16):3835-42. PubMed ID: 20564135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Involved node radiation therapy: an effective alternative in early-stage hodgkin lymphoma.
    Maraldo MV; Aznar MC; Vogelius IR; Petersen PM; Specht L
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1057-65. PubMed ID: 23200817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
    Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I
    Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of Hodgkin lymphoma: a 50-year perspective.
    Canellos GP; Rosenberg SA; Friedberg JW; Lister TA; Devita VT
    J Clin Oncol; 2014 Jan; 32(3):163-8. PubMed ID: 24441526
    [No Abstract]   [Full Text] [Related]  

  • 25. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.
    Okosun J; Warbey V; Shaw K; Montoto S; Fields P; Marcus R; Virchis A; McNamara C; Bower M; Cwynarski K
    AIDS; 2012 Apr; 26(7):861-5. PubMed ID: 22333746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial.
    Iannitto E; Minardi V; Gobbi PG; Calvaruso G; Tripodo C; Marcheselli L; Luminari S; Merli F; Baldini L; Stelitano C; Callea V; Petrini M; Angrilli F; Quarta G; Vallisa D; Molica S; Liardo E; Polimeno G; Brugiatelli M; Federico M
    Clin Lymphoma Myeloma; 2009 Apr; 9(2):138-44. PubMed ID: 19406724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evolving approaches to primary treatment of Hodgkin lymphoma.
    Connors JM
    Hematology Am Soc Hematol Educ Program; 2005; ():239-44. PubMed ID: 16304387
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma.
    Cerci JJ; Pracchia LF; Linardi CC; Pitella FA; Delbeke D; Izaki M; Trindade E; Soares J; Buccheri V; Meneghetti JC
    J Nucl Med; 2010 Sep; 51(9):1337-43. PubMed ID: 20720036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Our experiences in treating patients with Hodgkin disease in the last decade].
    Simon Z; Keresztes K; Miltényi Z; Ress Z; Váróczy L; Vadász G; Gergely L; Illés A
    Orv Hetil; 2007 Apr; 148(15):675-82. PubMed ID: 17416575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Sarcoidosis-like reaction after treatment with doxorubicin, bleomycin, vinblastine and dacarbazine in a patient with Hodgkin's lymphoma].
    Torrent A; Navarro JT; Andreo FC; Ribera JM
    Med Clin (Barc); 2013 Aug; 141(3):134-5. PubMed ID: 23332624
    [No Abstract]   [Full Text] [Related]  

  • 31. [Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center].
    Arranz R; Gil-Fernández JJ; Muñoz E; Acevedo A; Sobrino MP; Fernández-Rañada JM
    Sangre (Barc); 1998 Jun; 43(3):179-84. PubMed ID: 9741222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Resistance to first line chemotherapy treatment in a patient diagnosed of nodular lymphocyte-predominant Hodgkin's lymphoma identified by 18F-FDG PET/CT: diagnostic and therapeutic implications].
    Banzo J; Ubieto MA; Giraldo P; Razola P; Prats E; Tardin L; Santapau A; Parra A; Rambalde EF; Velilla J
    Rev Esp Med Nucl Imagen Mol; 2012; 31(2):89-92. PubMed ID: 21620527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Value of surveillance studies for patients with stage I to II diffuse large B-cell lymphoma in the rituximab era.
    Hiniker SM; Pollom EL; Khodadoust MS; Kozak MM; Xu G; Quon A; Advani RH; Hoppe RT
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):99-106. PubMed ID: 25863757
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission.
    Huntington SF; Svoboda J; Doshi JA
    J Clin Oncol; 2015 May; 33(13):1467-74. PubMed ID: 25823735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma.
    Kobe C; Kuhnert G; Kahraman D; Haverkamp H; Eich HT; Franke M; Persigehl T; Klutmann S; Amthauer H; Bockisch A; Kluge R; Wolf HH; Maintz D; Fuchs M; Borchmann P; Diehl V; Drzezga A; Engert A; Dietlein M
    J Clin Oncol; 2014 Jun; 32(17):1776-81. PubMed ID: 24799482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hodgkin's disease: summary of twenty years' experience.
    Mazza P; Bocchia M; Zinzani PL; Fiacchini M; Gherlinzoni F; Bandini G; Bendandi M; Frezza GP; Neri S; Barbieri E
    Haematologica; 1992; 77(6):487-93. PubMed ID: 1283856
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bleomycin-induced Raynaud's phenomenon after single-dose exposure: risk factors and treatment with intravenous iloprost infusion.
    McGrath SE; Webb A; Walker-Bone K
    J Clin Oncol; 2013 Feb; 31(4):e51-2. PubMed ID: 23270004
    [No Abstract]   [Full Text] [Related]  

  • 38. Relapse and late complications in early-stage Hodgkin's disease patients with mediastinal involvement treated with radiotherapy alone or plus one cycle of ABVD.
    Enrici RM; Anselmo AP; Donato V; Falchetto Osti M; Santoro M; Tombolini V; Mandelli F
    Haematologica; 1999 Oct; 84(10):917-23. PubMed ID: 10509040
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Routine Surveillance Imaging on the Outcomes of Patients With Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell Transplantation.
    Kapke JT; Epperla N; Shah N; Richardson K; Carrum G; Hari PN; Pingali SR; Hamadani M; Karmali R; Fenske TS
    Clin Lymphoma Myeloma Leuk; 2017 Jul; 17(7):408-414. PubMed ID: 28756899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin.
    Zinzani PL; Derenzini E; Pellegrini C; Celli M; Broccoli A; Argnani L
    Br J Haematol; 2013 Dec; 163(5):681-3. PubMed ID: 24032977
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.